H.C. Wainwright lowered the firm’s price target on Myomo (MYO) to $5 from $9.50 and keeps a Buy rating on the shares. The firm says that while the company’s Q2 ended well, there are warning signs ahead as Myomo reported that the number of patients added to its pipeline was significantly lower than expected.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYO: